Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Athira Pharma, Inc. ATHA
$2.93
-$0.02 (-0.68%)
На 18:03, 12 мая 2023
+514.33%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
108330691.00000000
-
week52high
9.92
-
week52low
2.22
-
Revenue
0
-
P/E TTM
-1
-
Beta
2.82228400
-
EPS
-2.61000000
-
Last Dividend
0.00000000
-
Next Earnings Date
10 мая 2023 г. в 10:59
Описание компании
Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company's lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in LIFT-AD Phase 3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease. It also develops product candidates, which are in preclinical stage, including ATH-1019 for peripheral nervous system indications; and ATH-1020 for neuropsychiatric conditions. Athira Pharma, Inc. was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. The company was incorporated in 2011 and is headquartered in Bothell, Washington.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Mizuho | Buy | 07 июл 2022 г. | |
| Stifel | Hold | Buy | 23 июн 2022 г. |
| JMP Securities | Market Perform | Market Outperform | 23 июн 2022 г. |
| Jefferies | Hold | Buy | 23 июн 2022 г. |
| BTIG | Buy | 10 мая 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Litton Mark James | A | 425000 | 425000 | 27 янв 2023 г. |
| MILESON GLENNA | A | 150000 | 150000 | 19 янв 2023 г. |
| MOEBIUS HANS | A | 200000 | 200000 | 19 янв 2023 г. |
| Worthington Mark | A | 150000 | 150000 | 19 янв 2023 г. |
| Lenington Rachel | A | 200000 | 200000 | 19 янв 2023 г. |
| CHURCH KEVIN | A | 150000 | 150000 | 19 янв 2023 г. |
| MILESON GLENNA | A | 159930 | 50000 | 28 дек 2022 г. |
| Romano Kelly A | A | 38315 | 30000 | 02 дек 2022 г. |
| Litton Mark James | A | 129217 | 662 | 18 ноя 2022 г. |
| CHURCH KEVIN | A | 62052 | 657 | 18 ноя 2022 г. |
Новостная лента
Athira Pharma to Present Preclinical Data Highlighting Therapeutic Potential of ATH-1105 in ALS at the 33rd International Symposium on ALS/MND
GlobeNewsWire
28 ноя 2022 г. в 07:00
HGF/MET small molecule positive modulator provides neuroprotection and improves motor and nerve function in a TDP-43 mouse model of ALS HGF/MET small molecule positive modulator provides neuroprotection and improves motor and nerve function in a TDP-43 mouse model of ALS
Athira Pharma to Present Additional Biomarker Data from ACT-AD Phase 2 Study of Fosgonimeton at the 2022 Clinical Trials on Alzheimer's Disease (CTAD) Conference
GlobeNewsWire
21 ноя 2022 г. в 07:00
Fosgonimeton demonstrates improvement on diverse biomarkers of neurodegeneration Fosgonimeton demonstrates improvement on diverse biomarkers of neurodegeneration
Athira Pharma to Present at Stifel 2022 Healthcare Conference
GlobeNewsWire
09 ноя 2022 г. в 07:00
BOTHELL, Wash., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that members of Athira's management team will participate in the Stifel 2022 Healthcare Conference taking place Nov. 15-16, 2022 in New York City. Members of management will participate in a fireside chat on Wednesday, Nov. 16, 2022 at 4:45 p.m. EST.
Athira Pharma to Present Preclinical Data Highlighting Therapeutic Potential of HGF/MET Platform in Neurodegenerative Disorders at Neuroscience 2022 Conference
GlobeNewsWire
07 ноя 2022 г. в 07:00
Data supports neuroprotective and disease modifying potential in models of Parkinson's disease and diabetic neuropathy Data supports neuroprotective and disease modifying potential in models of Parkinson's disease and diabetic neuropathy
Trading Ideas On The Upcoming CTAD 2022 Conference
Seeking Alpha
02 ноя 2022 г. в 15:27
The Clinical Trials on Alzheimer's Conference will take place from November 29, 2022 to December 2, 2022. Representatives of several listed companies will present data, including Eisai, Anavex, BioVie, Athira Pharma, Cassava Sciences and NervGen.